These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17351873)

  • 21. AMPA receptor-mediated cell death is reduced by docosahexaenoic acid but not by eicosapentaenoic acid in area CA1 of hippocampal slice cultures.
    Ménard C; Patenaude C; Gagné AM; Massicotte G
    J Neurosci Res; 2009 Mar; 87(4):876-86. PubMed ID: 18951489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-dependent postsynaptic AMPA GluR1 receptor recruitment in the cingulate synaptic potentiation.
    Toyoda H; Wu LJ; Zhao MG; Xu H; Zhuo M
    Dev Neurobiol; 2007 Mar; 67(4):498-509. PubMed ID: 17443804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute ampakine treatment ameliorates age-related deficits in long-term potentiation.
    Radin DP; Zhong S; Purcell R; Lippa A
    Biomed Pharmacother; 2016 Dec; 84():806-809. PubMed ID: 27721179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization, localization, and regulation of ionotropic glutamate receptors in skate horizontal cells.
    Kreitzer MA; Birnbaum AD; Qian H; Malchow RP
    Vis Neurosci; 2009; 26(4):375-87. PubMed ID: 19678977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid beta peptides and glutamatergic synaptic dysregulation.
    Parameshwaran K; Dhanasekaran M; Suppiramaniam V
    Exp Neurol; 2008 Mar; 210(1):7-13. PubMed ID: 18053990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic liver failure in rats impairs glutamatergic synaptic transmission and long-term potentiation in hippocampus and learning ability.
    Monfort P; Erceg S; Piedrafita B; Llansola M; Felipo V
    Eur J Neurosci; 2007 Apr; 25(7):2103-11. PubMed ID: 17439494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus.
    Yamin G
    J Neurosci Res; 2009 Jun; 87(8):1729-36. PubMed ID: 19170166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decline of long-term potentiation (LTP) in the rat auditory cortex in vivo during postnatal life: involvement of NR2B subunits.
    Hogsden JL; Dringenberg HC
    Brain Res; 2009 Aug; 1283():25-33. PubMed ID: 19520065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacologic treatment for cognitive disorders: an update].
    Lestage P
    Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.
    Moriguchi S; Shioda N; Han F; Narahashi T; Fukunaga K
    J Neurochem; 2008 Aug; 106(3):1092-103. PubMed ID: 18445137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging cognitive enhancing drugs.
    Buccafusco JJ
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):577-89. PubMed ID: 19772371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.
    Marenco S; Weinberger DR
    CNS Drugs; 2006; 20(3):173-85. PubMed ID: 16529524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMPA receptor potentiators: application for depression and Parkinson's disease.
    O'Neill MJ; Witkin JM
    Curr Drug Targets; 2007 May; 8(5):603-20. PubMed ID: 17504104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The AMPA modulator S 18986 improves declarative and working memory performances in aged mice.
    Marighetto A; Valerio S; Jaffard R; Mormede C; Muñoz C; Bernard K; Morain P
    Behav Pharmacol; 2008 May; 19(3):235-44. PubMed ID: 18469541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xenon reduces N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the amygdala.
    Haseneder R; Kratzer S; Kochs E; Eckle VS; Zieglgänsberger W; Rammes G
    Anesthesiology; 2008 Dec; 109(6):998-1006. PubMed ID: 19034096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competitive AMPA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Med Res Rev; 2007 Mar; 27(2):239-78. PubMed ID: 16892196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive modulators of AMPA receptors as a potential treatment for schizophrenia.
    Danysz W
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1062-6. PubMed ID: 12186268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced LTP of primary afferent neurotransmission in AMPA receptor GluR2-deficient mice.
    Youn DH; Royle G; Kolaj M; Vissel B; Randić M
    Pain; 2008 May; 136(1-2):158-67. PubMed ID: 17826911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.